MP-435 / Tanabe Pharma - LARVOL DELTA

[VIRTUAL] The Myeloperoxidase (MPO) Anti-Neutrophilic Cytoplasmic Antibody (ANCA) Binding Epitope, MPO447-459 Induces CD4 T-cell Proliferation in Patients with MPO-ANCA-associated Vasculitis (ACR-ARHP 2020) - "CD4+ T cells from patients with MPO-AAV proliferate specifically to the MPO447-459 epitope within the MPO heavy chain, and this response is greater after remission. An increased CDI to MPO435-465 suggests that MPO447-459 can be processed in culture from the longer peptide. T cell immunomodulation may be a suitable strategy for remitted MPO-AAV."

Clinical • Immune Modulation • Immunology • Infectious Disease • Inflammation • Tetanus • MPO

Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mitsubishi Tanabe; P2

Rheumatoid Arthritis

Efficacy and safety study of MP-435 in combination with methotrexate (MTX) in patients with rheumatoid arthritis (clinicaltrials.gov) - P2, N=100; Recruiting -> Active not recruiting

Enrollment closed • Rheumatoid Arthritis